Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
about
Cholinesterase inhibitors for rarer dementias associated with neurological conditionsMini-Cog for the diagnosis of Alzheimer’s disease dementia and other dementias within a secondary care settingMini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community settingCognitive training interventions for dementia and mild cognitive impairment in Parkinson’s DiseaseCholinesterase inhibitors for neurological conditions associated with rarer dementiasMini-Cog for the diagnosis of Alzheimer's disease dementia and other dementias within a community settingNew Drugs from Marine Organisms in Alzheimer's DiseasePersistence and adherence with dementia pharmacotherapy: relevance of patient, provider, and system factorsAlpha-synuclein biology in Lewy body diseasesParkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's diseaseAssessment and management of behavioral and psychological symptoms of dementiaParkinson's Disease and Cognitive ImpairmentTreatment of psychosis and dementia in Parkinson's disease.Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem).Magnetic resonance spectroscopy in the diagnosis of dementia with Lewy bodies.A Risk-Benefit Assessment of Dementia Medications: Systematic Review of the Evidence.The neurobiological basis of cognitive impairment in Parkinson's disease.Screening for impaired cognitive domains in a large Parkinson's disease population and its application to the diagnostic procedure for Parkinson's disease dementia.The spectrum of cognitive impairment in Lewy body diseasesTreatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.UPDATE ON DEMENTIA WITH LEWY BODIES.Clinical aspects of palliative care in advanced Parkinson's disease.Lewy body dementias.Capgras-like visual decomposition in Lewy body dementia with therapeutic response to donepezil.Characteristics of patients misdiagnosed with Alzheimer's disease and their medication use: an analysis of the NACC-UDS database.The monoaminergic footprint of depression and psychosis in dementia with Lewy bodies compared to Alzheimer's disease.Evaluation and management of the elderly patient presenting with cognitive complaints.Non-dopamine receptor ligands for the treatment of Parkinson's disease. Insight into the related chemical/property space.The Use of Bayesian Networks to Assess the Quality of Evidence from Research Synthesis: 2. Inter-Rater Reliability and Comparison with Standard GRADE Assessment.Parkinson's disease dementia: a neural networks perspective.Screening for Dementia in Older Adults: Comparison of Mini-Mental State Examination, Mini-Cog, Clock Drawing Test and AD8Screening for Mild Cognitive Impairment in Parkinson's Disease: Comparison of the Italian Versions of Three Neuropsychological Tests.Outcome measures for Parkinson's disease dementia: a systematic review.Cognitive rehabiliation for Parkinson's disease demantia: a study protocol for a pilot randomised controlled trialNicotinic receptors in neurodegeneration.Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive ImpairmentDrug Therapy for Behavioral and Psychological Symptoms of DementiaNeural Control of Walking in People with Parkinsonism.Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.
P2860
Q24187428-08BA1C19-AA4A-4760-AA73-036409A03D0CQ24187538-EC51EA3D-BEF6-4B37-B9B5-7E9E66A4510EQ24187908-4FCA155C-6FD6-402E-BB5F-6E4158CDE10AQ24188194-B12C41AD-F18B-48F1-A455-4958BB2ADA12Q24201472-30C87147-E177-4A36-A776-6DFFE5EC6C05Q24202610-81472F25-A2FF-41ED-912A-570E957BA14BQ26771804-ABA6E8D9-8EFA-4E42-B924-BD5699B9239AQ26997299-71BEC85E-480E-4675-80EC-6BAEE00F71CAQ27003541-2CD95074-027B-4002-97C3-188E6A7FF28EQ27686837-F128CB65-BCC1-4DCF-BD85-D57135551BEEQ28084380-00D501F6-5C41-4A98-A84C-46934D749C1BQ28088782-BDEDB1DA-6C16-4B0F-A92E-2ED5966400B0Q30239814-3933763C-6966-491C-BD60-282EDE8EBE92Q30358337-EBCE41E0-2451-4A14-BBC1-E488CBF89F2AQ30654813-095546D9-3792-4C15-831D-82D9C3A129B0Q30841801-05EF95C8-EF73-4F9F-8422-5932E3A535F5Q33165693-1DF60AAA-90EC-4891-8DAE-5BB38F0A79DAQ33724698-ADA386EC-63E9-4FAF-80F5-CCD518C18555Q33795176-2075DD21-7D6A-45F2-9F2E-406E9B8359CCQ34019751-67A4E372-2A55-4FA5-A964-C58C5824E8ADQ34388686-9B933354-FDD8-4ABB-89E3-87583EF0A1B3Q34450376-0AD59F0F-F7BF-4B1C-AD7D-9CE0F1C3A112Q34457767-E6AF7C73-6793-4375-98A9-3213A1D62B11Q34502646-2C91BFD9-B3E3-4453-A912-D0FB8DC84845Q34777851-1B98709C-58CC-4C99-A238-D24BA3F4C8CAQ35071880-F231A787-F27A-46A1-8D35-956185F42868Q35119259-5B253877-EFD1-4635-80B6-CCC3500B2BF7Q35447239-403EB206-9F8C-4575-AACA-EFF485069792Q35625767-BA1BBDD0-6B35-4C87-AE40-4630F4B0BAA5Q35881669-161771E0-3E67-45E7-8AE5-E415351D9A0EQ36186763-5651EBB9-E935-468B-B40C-BA976037B700Q36231823-694A44BC-85C1-4608-B9D9-1E7E85D003A2Q36304622-C0AD163A-AE58-468E-9CD3-13C239CC6F94Q36688859-532EE6BB-F5E6-4591-B3BA-8697FCD3374AQ36715018-7BF2D2D3-AF25-459C-80DE-31FB2929F20EQ36828916-3E7CC691-855D-4D77-9626-B4B23174BEC6Q36908486-FDC80061-6E87-4C48-BD05-86052F962372Q36925888-3DAD2E96-DB50-4AA2-B4E8-C512CA19A260Q36956319-B61DDE27-6880-48DB-A24F-7D603330F794Q37490737-E7E81A27-126C-4D83-8C18-00B37BC335B9
P2860
Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@ast
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en-gb
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@nl
type
label
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@ast
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en-gb
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@nl
prefLabel
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@ast
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en-gb
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@nl
P2093
P2860
P3181
P1476
Cholinesterase inhibitors for ...... airment in Parkinson's disease
@en
P2093
Ian Maidment
Michal Rolinski
Rupert McShane
P2860
P3181
P356
10.1002/14651858.CD006504.PUB2
P577
2012-03-14T00:00:00Z